Health

STAT+: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence

On Tuesday, Sellas said the therapy, called galinpepimut-S, reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia (AML) — an outcome that achieved the main goal of a Phase 3 clinical trial, the company said.

✦ Extractive summary — built from the sources' own reporting•From 1 source•1 min read•Updated November 17, 2026, 12:00 PM UTC
Key points
  • The randomized Phase 3 study enrolled 367 patients with intermediate-risk bladder cancer, a localized form of the disease that is typically removed in a minimally invasive surgical procedure.
  • Physicians use a catheter to infuse “creto” directly into the bladder, where it enters the mutated cancer cells, replicates rapidly, then breaks open the cells, killing them.
  • If the cancer returns, repeat surgical procedures can be performed, but over time, patients lose bladder function and the cancer can continue to grow.

It looks like I was wrong about Sellas Life Sciences and its experimental blood cancer immunotherapy.

Additional details
  • Continue to STAT+ to read the full story….
  • The CG Oncology treatment, called cretostimogene, is made from a type of common cold virus engineered to target cells that express a specific mutation found in bladder tumors.
  • In a column published in September, I predicted galinpepimut would fail to prolong survival in the Phase 3 study.
  • Patients are then monitored every three months.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Advertisement

Every article behind this summary — 2 articles from 1 outlet